Expressive

rs10946737 - RIPOR2

Magnitude 4.5 · 1 study on file

Reported associations

  • Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity - Unknown journal (n.d.) · Unknown authors · PubMed 27671213

    ABSTRACT: Background Drug-induced liver injury (DILI) is a well-recognized adverse event of anti tuberculosis drugs (ATD) possibly associated with genetic variations. The objective of this study was to perform genome-wide association study (GWAS) to identify genetic variants associated with the risk for ATD induced liver toxicity in Ethiopian patients. Result Treatment-naïve newly diagnosed tuberculosis patients (n = 646) were enrolled prospectively and treated with rifampicin based short course anti-tuberculosis therapy. Whole genome genotyping was done using Illumina Omni Express Exome Bead Chip genotyping array with 951,117 single nucleotide polymorphisms (SNPs) on 48 DILI cases and 354 ATD tolerants. Replication study was carried out for 50 SNPs with the lowest P-values (top SNPs)

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Bloodwork

  • liver function tests during TB drug treatment Moderate

    Genetic susceptibility to TB drug hepatotoxicity requires enhanced surveillance of ALT, AST, ALP, and bilirubin for early injury detection.

    If taking TB drugs: baseline before treatment, then every 1-4 weeks during intensive phase, monthly during continuation phase

Discuss with your doctor

  • genetic risk for TB drug-induced liver injury Moderate

    rs10946737-A allele increases anti-TB drug-induced liver injury risk 3.4-fold; carriers require liver-protective planning if TB treatment needed.

    Before TB treatment initiation, inform prescriber of genotype and establish baseline liver function and monitoring plan

Lifestyle

  • alcohol during TB drug treatment Moderate

    Alcohol and TB drugs are synergistically hepatotoxic; combined exposure substantially elevates liver injury risk in genetically susceptible carriers.

    Complete alcohol abstinence during entire TB treatment course (typically 6 months)